Respinova Granted FDA 510(k) Clearance for Pulsehaler
Respinova has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Pulsehaler™. Pulsehaler™ is an innovative device that facilitates the opening
KAHR’s Anti-CD47 in Blood Cancers Clinical Trials Funded by Texas MD Anderson Cancer Focus Fund
KAHR, a Jerusalem based clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, and Cancer Focus Fund, LP, a unique venture capital fund established in
Jerusalem Startup eggXYt Launches Bid to Disrupt The Egg Industry
eggXYt, a Jerusalem-based genetic tech startup, is developing technology to save billions of baby chickens from unnecessary death, while generating significant savings for farmers. eggXYt
SpliSense Raises $28.5 Million for Treatment of CF
Jerusalem-based biopharmaceutical company SpliSense, which is developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, announced on Thursday the closing of
Smoking Cessation Becomes BrainsWay’s 3rd Noninvasive Brain Disorder Treatment
BrainsWay Ltd., a global leader in advanced noninvasive treatment of brain disorders, has started the distribution of its first 10 Deep Transcranial Magnetic Stimulation (Deep
Purple Biotech Initiates Phase 1b/2 Clinical Trial of CM24 Therapy for Non-Small Cell Lung Cancer & Pancreatic Cancer
Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today
Oramed JV, Oravax Medical, & India’s Premas Biotech to Develop Oral COVID-19 Vaccines
Jerusalem’s clinical-stage pharmaceutical company Oramed Pharmaceuticals is forming a joint venture with Premas Biotech , a biotechnology firm based in Gurugram, India, to develop novel oral
Pepticom’s New Spinout Company, PeptiCov, to Focus on COVID-19
Pepticom, a leader in artificial intelligence peptide drug design and discovery, announced today that it has raised $2.6 million to establish a company to focus
BrainsWay Ltd. Closes $45.2 Million Underwritten Public Offering of American Depositary Share
BrainsWay Ltd. (NASDAQ & TASE: BWAY) a global leader in the advanced noninvasive treatment of brain disorders, closed its previously announced underwritten public offering of
